Research programme: infected burns therapeutics - Creative Antibiotics
Alternative Names: INP 1750/1855; INP 341Latest Information Update: 13 Oct 2021
At a glance
- Originator Innate Pharmaceuticals AB
- Developer Creative Antibiotics
- Class
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pseudomonal-infections in Sweden
- 27 Oct 2011 Creative Antibiotics and AMRI collaborate to discover and develop antibiotics inhibiting T3SS virulence mechanism